title: [Treatment of severe steroid-refractory graft-versus-host disease with IL-2R alpha chain (CD25) monoclonal antibody].
abstract: OBJECTIVE
  To investigate the effects of IL-2R alpha chain (CD(25)) monoclonal antibody on severe steroid-refractory graft-versus-host disease (GVHD).
  
  
  METHODS
  Seventeen patients (18 times) with severe steroid-refractory GVHD were treated with intravenous drip of humanized CD(25) monoclonal antibody on day 1, 3 or 4, 8, 15 and 22. The cumulative scoring of GVHD and status of infection were observed, and laboratory tests, including blood counting and blood biochemical test were made before and 1, 4, 8, 15, 22, 29, 36, 43 and 50 days after the treatment.
  
  
  RESULTS
  (1) Eleven of the eighteen case-times (61.1%) got complete relief, five (27.8%) GVHD got partial relief, and two (11.1%) failed to get relief. (2) Seven case-times (33.3%) had infection. (3) Relapse of GVHD occurred in four of the eleven case-times with complete relief (36.4%). (4) No infusion-related reaction was observed.
  
  
  CONCLUSIONS
  The monoclonal antibody against IL-2 receptor alpha chain (CD(25)) has a marked effect upon severe steroid-refractory GVHD.
authors.affiliation: Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Lu
authors.forename: Lan-ping
authors.initials: LP
authors.lastname: Xu
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Huang
authors.forename: Huan
authors.initials: H
authors.lastname: Chen
authors.forename: Yao-chen
authors.initials: YC
authors.lastname: Zhang
authors.forename: Han-yun
authors.initials: HY
authors.lastname: Ren
authors.forename: Nai-lan
authors.initials: NL
authors.lastname: Guo
authors.forename: Dao-pei
authors.initials: DP
authors.lastname: Lu
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D004361:Drug Tolerance; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000009:adverse effects*; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2; D008775:Methylprednisolone